Citigroup
BCAX

Citigroup’s Bicara Therapeutics BCAX Stock Holding History

Citigroup’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
9,585
-57,112
-86% -$983K ﹤0.01% 4028
2025
Q4 		$1.12M Buy
66,697
+66,041
+10,067% +$1.13M ﹤0.01% 3070
2025
Q3 		$10.4K Sell
656
-10,864
-94% -$122K ﹤0.01% 5013
2025
Q2 		$107K Sell
11,520
-5,938
-34% -$70.8K ﹤0.01% 4373
2025
Q1 		$227K Buy
17,458
+1,970
+13% +$26.2K ﹤0.01% 4131
2024
Q4 		$270K Buy
15,488
+15,236
+6,046% +$317K ﹤0.01% 4222
2024
Q3 		$6.42K Buy
+252
New +$6.43K ﹤0.01% 5335

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Citigroup's BCAX Position: Q1 2026 in Review

Citigroup reduced its Bicara Therapeutics (BCAX) stake by 86% in Q1 2026, selling an estimated $983K and leaving 9,585 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

Citigroup first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.12M in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Citigroup held 9,585 shares of Bicara Therapeutics worth $191K as of Q1 2026.
  • Citigroup sold 57,112 Bicara Therapeutics shares in Q1 2026, an estimated $983K.
  • Bicara Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4028 holding.
  • Citigroup first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Citigroup's Bicara Therapeutics position peaked at $1.12M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.